Market Signal Briefing

December 07, 2025 2:16 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline.

SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the DexCom class action, go to https://rosenlegal.com/submit-form/?case_id=28133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to the G6 and G7 continuous glucose monitoring ("CGM") systems that were unauthorized by the U.S. Food and Drug Administration (the "FDA"); (2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (3) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (4) Defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (5) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (6) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the DexCom class action, go to https://rosenlegal.com/submit-form/?case_id=28133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277159

December 07, 2025 2:28 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jayud Global Logistics Ltd. (NASDAQ: JYD) between April 21, 2023 and April 30, 2025, both dates inclusive (the "Class Period"), of the important January 20, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Jayud securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Jayud class action, go to https://rosenlegal.com/submit-form/?case_id=48196 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Jayud was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) Jayud's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price; and (4) as a result of the foregoing, defendants' positive statements about Jayud's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To join the Jayud class action, go to https://rosenlegal.com/submit-form/?case_id=48196 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277200

December 07, 2025 2:30 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Primo Water Corporation (NYSE: PRMW) between June 17, 2024 and November 8, 2024, both dates inclusive, and/or (ii) purchasers of common stock of Primo Brands Corporation (NYSE: PRMB) between November 11, 2024 and November 6, 2025 (the "Class Period"), of the important January 12, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Primo Brands securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Primo Brands class action, go to https://rosenlegal.com/submit-form/?case_id=47890 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, Primo Brands formed following the November 8, 2024 merger between Primo Water and BlueTriton Brands, is a branded beverage company that offers beverage products across a variety of formats, channels, and price points. According to the lawsuit, throughout the Class Period, defendants misrepresented and failed to disclose key facts about the merger between Primo Water and BlueTriton Brands, including facts regarding the progress of the merger integration. Defendants issued a series of materially false and misleading statements that led investors to believe the merger would accelerate growth, generate transformative operational efficiencies, achieve meaningful synergies, and deliver strong financial results, and that the merger integration was proceeding "flawlessly." When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Primo Brands class action, go to https://rosenlegal.com/submit-form/?case_id=47890 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277202

Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript

Data infrastructure company Vertiv is benefiting from AI investments. But has it paid off for shareholders?

Ohio-based Vertiv Holdings (VRT +3.42%) was a sleepy company making electrical and infrastructure components like power converters and server racks for a number of industries. Lately, though, the products it manufactures for data centers have come into focus thanks to the artificial intelligence (AI) boom.

While that's made the company more exciting to investors, it's also made the stock more volatile. Currently more than 10% off its recent highs, has Vertiv stock paid off for its short-term and long-term shareholders?

Image source: Getty Images.

One year: Up after a big scare
Investors who bought Vertiv stock a year ago got off to a pleasant start as shares rose 20.8% in January, but for months afterward, the stock was underwater. At one point in April, it was down by 53.2%. A months-long recovery followed, and despite the stock's recent dip, shares are now 40.8% higher than they were a year ago.

That easily bests the S&P 500, which has only returned 13.4% over the past year. But how have longer-term investors fared?

Three years: Wow. Just wow.
Vertiv's shares really began to pop in mid-2023, and they continued their outperformance into 2024. That's boosted the stock's three-year return to an absolutely phenomenal 1,110%. Even though the S&P 500 has done well by historical standards over the last three years, rising 68.3%, it doesn't even come close to matching Vertiv's returns.

If the three-year returns are so good, the five-year returns must be even better, right?

Five years: Still wow, but not as much
Actually, Vertiv's current five-year return isn't as good as its three-year return:

Today's Change

(

3.42

%) $

6.24

Current Price

$

188.78

Don't get me wrong: It's still completely crushing the market with an 822.3% return, compared to the S&P 500's five-year return of just 86.7%, but that's almost 300 percentage points less than its three-year return. What happened?

In short, 2022 happened. That year, Vertiv's shares fell off a cliff in February after a disastrous Q4 2021 earnings report, in which the company reported a $3.9 million operating loss compared to a $120 million operating profit the year prior, along with a 95% drop in free cash flow. At one point, the company's share price was down 67% for the year.

Vertiv's three-year returns start from December 2022, meaning they don't suffer from the company's poor early 2022 performance. It's an excellent reminder that sometimes when a stock you own drops in price, the best move an investor can make is to buy the dip. Those who sold their Vertiv shares after 2022's drop lost money, but those who held on -- or better yet, bought more -- have generated market-crushing results.

HomeETFs and Funds AnalysisETF Analysis

SummaryAmerican Century Focused Dynamic Growth ETF (FDG) is rated Buy for its consistent outperformance versus the Russell 1000 Growth ETF and SPY.
FDG’s concentrated portfolio of 30–45 high-growth companies, selective sector tilts, and AI leadership bets have driven alpha over multiple time frames.
The ETF’s 0.45% expense ratio is only modestly higher than passive peers, justified by robust risk-adjusted returns and differentiated active management.
FDG’s higher beta (1.36) and Sharpe ratio (1.21) reflect its strong risk-reward profile, with management’s track record supporting continued outperformance.
Jonathan Kitchen/DigitalVision via Getty Images

FDG Overview The American Century Focused Dynamic Growth ETF (FDG) is an actively managed exchange-traded fund (also known as an ETF) that invests in a concentrated portfolio of mid- to large-cap growth companies with long-term capital

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in FDG, over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Quick Insights

Recommended For You

NEW YORK, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marex Group plc (“Marex” or “the Company”) (NASDAQ: MRX) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marex securities between May 16, 2024 and August 5, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/MRX.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Marex sold over-the-counter financial products to itself, creating undisclosed conflicts of interest; (2) The Company’s financial statements contained significant inconsistencies between subsidiaries and related parties; (3) As a result of these discrepancies, Marex’s financial statements were not reliable; (4) Based on these facts, the Company’s public statements regarding its business, operations, and financial condition were false and materially misleading throughout the Class Period; (5) When the market learned the truth about Marex, investors suffered damages.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/MRX. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Marex you have until December 8, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

FRANKLIN, IN / ACCESS Newswire / December 7, 2025 / IBC Advanced Alloys Corp. ("IBC" or the "Company") (TSX-V:IB)(OTCQB:IAALF) announces the results of its 2025 Annual General Meeting (the "Meeting"), held on December 5, 2024, in Centennial, CO.

At the Meeting, the Shareholders re-elected to the board of directors by ordinary resolution, Mark A. Smith, Simon Anderson, Geoff Hampson, Mike Jarvis, and Chris Huskamp to serve in office until the next annual general meeting of Shareholders or until their successors are duly elected or appointed. In addition, the Shareholders set the number of Directors of the Company at five, voted in favor of the appointment of Crowe MacKay LLP as auditors of the Company, and to re-approve the Company's amended and restated stock option plan.

For more information on IBC and its innovative alloy products, go here.

On Behalf of the Board of Directors:

"Mark A. Smith"

Mark Smith, Chairman of the Board

# # #

Contacts:

Mark A. Smith, Chairman of the Board
Jim Sims, Director of Investor and Public Relations
+1 (303) 503-6203
Email: [email protected]
Website: www.ibcadvancedalloys.com

@IBCAdvanced $IB $IAALF #copper

ABOUT IBC ADVANCED ALLOYS CORP.

IBC is a leading advanced copper alloys manufacturer serving a variety of industries such as defense, aerospace, automotive, telecommunications, precision manufacturing, and others. At its vertically integrated production facility in Franklin, Indiana, IBC manufactures and distributes a variety of copper alloys as castings and forgings, including beryllium copper, chrome copper, and aluminum bronze. The Company's common shares are traded on the TSX Venture Exchange under the symbol "IB" and the OTCQB under the symbol "IAALF".

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy of this news release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE: IBC Advanced Alloys Corp.

, /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bitdeer Technologies Group ("Bitdeer" or "the Company") (NASDAQ: BTDR) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bitdeer securities between June 6, 2024 and November 10, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/BTDR.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Defendants provided overwhelmingly positive statements to investors while concealing material adverse facts regarding the true state of Bitdeer's SEALMINER A4 project; (2) Defendants failed to disclose that the SEAL04 chip, projected to achieve a chip-level energy efficiency of 5 J/TH, would not be ready for use in the A4 rigs as represented; and (3) Mass production of the SEAL04 chip was not expected to begin in the second quarter of 2025 as previously indicated.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/BTDR. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Bitdeer you have until February 2, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC

- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit
- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable efficacy
- More than 75 individuals across eight countries have received HEMGENIX in real-world settings, reflecting growing global adoption

, /PRNewswire/ -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study, confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec-drlb) in adults living with hemophilia B. Published in the New England Journal of Medicine (NEJM) and presented simultaneously at the American Society of Hematology (ASH) Annual Meeting, the data reaffirm HEMGENIX's consistent performance over time to deliver durable factor IX activity levels, sustained bleed protection compared to prophylaxis treatment, and continued freedom from routine prophylaxis. HEMGENIX remains the only commercially available gene therapy for adults with hemophilia B and can be used in patients with or without AAV5 neutralizing antibodies.

"The five-year HOPE-B results mark a pivotal milestone for gene therapy, providing clear, long-term data of the ability of HEMGENIX to potentially transform care for adults with hemophilia B," said Steven Pipe, MD, Professor of Pediatrics and Pathology, Hemophilia and Coagulation Disorders Program and the Special Coagulation Laboratory, University of Michigan. "For those who have relied on frequent prophylactic infusions, achieving lasting bleed control from a single treatment offers the potential for greater day-to-day freedom and a life less burdened by the demands of ongoing therapy."

In the Phase 3, open-label, single-dose, single-arm HOPE-B trial, 54 adult male participants with severe or moderately severe hemophilia B, with or without preexisting AAV5 neutralizing antibodies, were infused with a single dose of HEMGENIX. Of the 54 participants, 50 completed five years of follow-up. The five-year follow-up analysis demonstrated:

Durable Factor IX Activity: Mean factor IX activity levels were sustained at greater than 36% during years one through five post-infusion: mean factor IX levels of 41.5 IU/dL (n=50) at year one, 36.7 IU/dL (n=50) at year two, 38.6 IU/dL (n=48) at year three, 37.4 IU/dL (n=47) at year four, and 36.1 IU/dL (n=48) at year five.
Sustained Bleed Protection: The mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by approximately 90% from the lead-in (4.16, n=54) compared to year five (0.40, n=51) post-infusion. Additionally, joint bleeds were reduced by 93% from lead-in (mean ABR of 2.34 at lead-in to 0.16 at year five) and spontaneous bleeds were reduced by 94% (mean ABR of 1.52 during lead-in versus 0.09 during year five).
Freedom from Prophylaxis: 94% of patients remained free of continuous prophylaxis treatment following their one-time gene therapy infusion. This rate has remained consistent over time, with only one participant resuming continuous factor IX prophylaxis at month 30 post-infusion.
Favorable Safety Profile: No serious adverse events were related to treatment with HEMGENIX. HEMGENIX was generally well-tolerated, with a total of 100 treatment-related adverse events (TRAEs), most of which occurred in the first four months post-infusion. Only five TRAEs were reported between years four and five. The most common adverse events were an increase in alanine transaminase (ALT), for which nine (16.7%) participants received supportive care with reactive corticosteroids for a mean duration of 81.4 days (standard deviation: 28.6; range: 51-130 days).

"We are incredibly proud to share the five-year results from the HOPE-B study, which reinforce the lasting impact of HEMGENIX as a one-time treatment option for adults with hemophilia B," said Deborah Long, MD, FCCP, Senior Vice President and Head, Medical Affairs, CSL. "These results highlight the meaningful difference HEMGENIX can make—helping people experience fewer bleeds compared to prophylaxis treatment and freeing them from the burden of regular ongoing treatment. We remain committed to expanding access to this important treatment."

Although the five-year data mark the final analysis for the HOPE-B study, participants who consent will continue to be monitored in the IX-TEND 222-3003 extended follow-up study (NCT05962398), which will track patients for up to 15 years post-treatment.

The multi-year clinical development of HEMGENIX was led by uniQure (Nasdaq: QURE) and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialize the treatment. CSL also established a post-marketing registry to generate additional long-term safety, efficacy and durability data.

HEMGENIX has received regulatory approval in the United States, Canada, the UK, Switzerland, Australia, Saudi Arabia, Taiwan, South Korea, Singapore, and Hong Kong, and conditional marketing authorization from the European Commission (EC) for the European Union and European Economic Area. To date, more than 75 individuals across eight countries have received HEMGENIX in real-world settings.

For more information on HEMGENIX, please visit www.Hemgenix.com.

About the Pivotal HOPE-B Trial
The pivotal Phase 3 HOPE-B trial is an ongoing, multinational, open-label, single-arm study to evaluate the safety and efficacy of HEMGENIX. Fifty-four adult male participants with severe or moderately severe hemophilia B, with or without preexisting AAV5 neutralizing antibodies, were enrolled in a prospective, six-month or longer observational period during which time they continued to use their current standard-of-care therapy to establish a baseline ABR. After at least the six-month lead-in period, patients received a single intravenous administration of HEMGENIX at a 2x10^13 gc/kg dose. Patients were not excluded from the trial based on preexisting neutralizing antibodies (NAbs) to AAV5.

A total of 54 patients received a single dose of HEMGENIX in the pivotal trial, with 50 patients completing five years of follow-up. The primary endpoint in the pivotal HOPE-B study was ABR 52 weeks after achievement of stable factor IX expression (months seven to 18) compared with the six-month lead-in period. For this endpoint, ABR was measured from month seven to month 18 after infusion, ensuring the observation period represented a steady-state factor IX transgene expression. Secondary endpoints included assessment of factor IX activity.

No serious treatment-related adverse reactions (TRAEs) were reported. Two deaths occurred during the study due to non-treatment-related TRAEs: one at approximately 15 months post-dose due to cardiogenic shock and urosepsis, and another at approximately 54 months post-dose due to cardiac amyloidosis. A serious adverse event of myelodysplastic syndrome was initially assessed by the investigator as possibly treatment-related; however, following the results of molecular analysis and based on the assessment of risk factors, the investigator reassessed the event as not treatment-related after the five-year clinical database lock for the study. No inhibitors to factor IX were reported.

About Hemophilia B
Hemophilia B is a life-threatening rare disease caused by a mutation on the F9 gene, resulting in low levels of functional clotting factor IX. People with the condition are particularly vulnerable to bleeds in their joints, muscles, and internal organs, leading to pain, swelling, and joint damage. Treatments for moderate to severe hemophilia B typically include life-long prophylactic infusions of factor IX to temporarily replace or supplement low levels of the blood-clotting factor. Beyond the physical burden, many people with hemophilia B are continually confronted with the mental and emotional impact of managing their condition—and rarely have their minds free of hemophilia.

About HEMGENIX
HEMGENIX is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B. It uses AAV5, a non-infectious viral vector, called an adeno-associated virus (AAV). The AAV5 vector carries the Padua gene variant of Factor IX (FIX-Padua) to the target cells in the liver, generating factor IX proteins that are 8x more active than normal. These genetic instructions remain in the target cells, but generally do not become a part of a person's own DNA. Once delivered, the new genetic instructions allow the cellular machinery to produce stable levels of factor IX.

Important Safety Information (ISI)

What is HEMGENIX?
HEMGENIX®, etranacogene dezaparvovec-drlb, is a one-time gene therapy for the treatment of adults with hemophilia B who:

Currently use Factor IX prophylaxis therapy, or
Have current or historical life-threatening bleeding, or
Have repeated, serious spontaneous bleeding episodes.

HEMGENIX is administered as a single intravenous infusion and can be administered only once.

What medical testing can I expect to be given before and after administration of HEMGENIX?
To determine your eligibility to receive HEMGENIX, you will be tested for Factor IX inhibitors. If this test result is positive, a retest will be performed 2 weeks later. If both tests are positive for Factor IX inhibitors, your doctor will not administer HEMGENIX to you. If, after administration of HEMGENIX, increased Factor IX activity is not achieved, or bleeding is not controlled, a post-dose test for Factor IX inhibitors will be performed.

HEMGENIX may lead to elevations of liver enzymes in the blood; therefore, ultrasound and other testing will be performed to check on liver health before HEMGENIX can be administered. Following administration of HEMGENIX, your doctor will monitor your liver enzyme levels weekly for at least 3 months. If you have preexisting risk factors for liver cancer, regular liver health testing will continue for 5 years post-administration. Treatment for elevated liver enzymes could include corticosteroids.

What were the most common side effects of HEMGENIX in clinical trials?
In clinical trials for HEMGENIX, the most common side effects reported in more than 5% of patients were liver enzyme elevations, headache, elevated levels of a certain blood enzyme, flu-like symptoms, infusion-related reactions, fatigue, nausea, and feeling unwell. These are not the only side effects possible. Tell your healthcare provider about any side effect you may experience.

What should I watch for during infusion with HEMGENIX?
Your doctor will monitor you for infusion-related reactions during administration of HEMGENIX, as well as for at least 3 hours after the infusion is complete. Symptoms may include chest tightness, headaches, abdominal pain, lightheadedness, flu-like symptoms, shivering, flushing, rash, and elevated blood pressure. If an infusion-related reaction occurs, the doctor may slow or stop the HEMGENIX infusion, resuming at a lower infusion rate once symptoms resolve.

What should I avoid after receiving HEMGENIX?
Small amounts of HEMGENIX may be present in your blood, semen, and other excreted/secreted materials, and it is not known how long this continues. You should not donate blood, organs, tissues, or cells for transplantation after receiving HEMGENIX.

Please see full prescribing information for HEMGENIX.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You can also report side effects to CSL Behring's Pharmacovigilance Department at 1-866-915-6958. 

About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop, and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita. 

For more information about CSL, visit CSL.com.

Media Contacts
Etanjalie Ayala, CSL
Mobile: +1 610 297 1069
Email: [email protected]

Stephanie Fuchs, CSL
Mobile: +49 151 58438860
Email: [email protected]

SOURCE CSL

It may surprise you to learn what's driving long-term profitability at the General Electric spinoff.

Long-term General Electric followers and investors will be well aware of the remarkable turnaround in GE Vernova's (GEV +0.35%) fortunes. A spinoff from the former GE (the remaining company is GE Aerospace), GE Vernova was once the problem child in the industrial conglomerate. Still, it is now the highest-rated stock (by valuation multiples) among the remaining GE companies.

It's an incredible turnaround, but can it last? Here are two things you need to know before investing in the stock.

Today's Change

(

0.35

%) $

2.21

Current Price

$

631.32

1. GE Vernova is an artificial intelligence play
The enterprise value (market capitalization plus net debt) to earnings before interest, taxes, depreciation, and amortization (EBITDA) valuations for the three GE stocks demonstrate this point. It's an impressive turnaround, as GE's power operations were deemed its weak link.

Data by YCharts.

Back in the tumultuous 2015-2020 period, many investors concluded that its core power business of gas turbine equipment and services was destined for, at best, long-term, low single-digit growth as the seemingly inexorable rise of renewable energy rendered gas technology less relevant. Moreover, the electrification and grid technology businesses were seen as low-growth and ultimately driven by the replacement cycle for power equipment.

A few years later, the surging demand for power to support AI application-led demand from data centers has transformed matters. In addition, the growing realization that the energy transition (although still ongoing) would not happen at the previously envisaged pace due to surging costs means a new normal is now in place.

Image source: Getty Images.

Of course, GE Vernova also has a renewable energy business, specifically focusing on wind energy (onshore and offshore wind turbines and services). The fact that it remains loss-making speaks volumes to the reality of renewable energy.

GE Vernova is, in effect, a response to the growth in AI applications and the consequent increase in power demand.

This is clearly evident in its backlog growth during the third quarter. As such, if you are fearful of an AI bubble, then this is a stock to avoid. On the other hand, it represents an excellent backdoor way to play a long cycle of growth in AI-led investment.

Backlog

Q3 2025

Q3 2024

Growth

Power

$84.1 billion

$71.3 billion

18%

Electrification

$30.2 billion

$21.9 billion

38%

Wind

$21.5 billion

$25 billion

(14)%

Data source: GE Vernova presentations. Table by the author.

2. Don't underestimate the wind power business
GE Vernova appears to have turned full circle, and few investors now focus on its loss-making wind power business. However, that approach could be a mistake, as wind is likely to turn into an earnings contributor in the future.

Image source: Getty Images.

The wind segment is a tale of two businesses, with onshore wind being profitable, but offshore wind creating ongoing losses from large contracts entered into a few years earlier. Management's strategy is to prioritize executing existing offshore wind contracts over pursuing new ones, while developing the onshore wind business. As such, management expects it will return the wind segment EBITDA margin to 10% in 2028 from -6.1% EBITDA margin in 2024.

It all means that investors shouldn't write off the wind business as a profit center in the future, as it supports long-term growth in the power and electrification segments.

Strong fundamentals beneath a volatile stock—here’s why the latest buyer may be betting early on the next leg of growth.

On November 14, California-based Tensile Capital Management disclosed a new position in Champion Homes (SKY +2.25%), acquiring 308,162 shares valued at approximately $23.5 million, according to its latest SEC filing.

What HappenedAccording to a filing submitted to the U.S. Securities and Exchange Commission on November 14, Tensile Capital Management LP established a new holding in Champion Homes. The position totals 308,162 shares with a reported market value of $23.5 million as of the quarter ending September 30.

What Else to KnowThe position represents 2.9% of Tensile's $800.4 million in U.S. equity holdings reported in the third-quarter filing.

Top holdings after the filing: 

NASDAQ: VERX: $94.3 million (11.8% of AUM)NYSE: DKS: $79.5 million (9.9% of AUM)NYSE: VVV: $74.7 million (9.3% of AUM)NYSE: LAD: $74.4 million (9.3% of AUM)NYSE: USFD: $58.5 million (7.3% of AUM)As of Friday, shares of Champion Homes were priced at $85.38, down 18% over the past year and well underperforming the S&P 500, which is up 13% in the same period.

Company OverviewMetricValuePrice (as of market close Friday)$85.38Market capitalization$4.8 billionRevenue (TTM)$2.6 billionNet income (TTM)$220.8 millionCompany SnapshotChampion Homes produces and sells factory-built housing, including manufactured and modular homes, park model RVs, accessory dwelling units, and modular buildings for multi-family and hospitality applications.The company generates revenue through the design, manufacture, and direct sale of factory-built homes, as well as construction services, transportation, and a network of company-owned retail centers.It serves homebuyers, real estate developers, and institutional clients across North America, with a focus on the United States and western Canada.Champion Homes is a leading North American provider of factory-built housing solutions, operating under multiple well-known brands. The company leverages an integrated business model that spans manufacturing, retail, installation, and transportation, enabling efficient delivery and customization of residential and commercial structures. With a diversified product portfolio and a strong presence in both the United States and Canada, Champion Homes is positioned to address a wide range of housing needs in the residential construction market.

Foolish TakeChampion’s volatility this year makes an institutional move like this meaningful, especially when fundamentals have strengthened despite a choppy housing backdrop. Tensile’s entry comes after the company delivered another quarter of solid execution, with net sales up 11% to $684.4 million and EPS rising nearly 10% to $1.03 as factory-built housing demand held firm. The company also expanded gross margin to 27.5%, boosted backlog, and generated $75.9 million in operating cash while repurchasing $50 million of stock. Those operational trends create a clearer long-term earnings runway than the stock’s recent pullback suggests.

Within Tensile’s portfolio, Champion becomes a mid-sized but meaningful position at 2.9% of assets—consistent with the firm’s pattern of accumulating category leaders with defensible unit economics. For long-term investors, Champion’s integrated retail, manufacturing, and logistics model, combined with steady price and volume gains, supports durability even in uncertain housing cycles.

Glossary13F reportable assets: Investment holdings that institutional managers must disclose quarterly to the SEC on Form 13F.
Assets under management (AUM): The total market value of investments managed by a fund or investment firm.
Compound annual growth rate (CAGR): The annualized rate of return for an investment over a specified period, assuming profits are reinvested.
Trailing twelve months (TTM): The 12-month period ending with the most recent quarterly report.
Factory-built housing: Homes or buildings constructed in a factory and then transported to their final site for installation.
Modular homes: Homes built in sections in a factory, then assembled on-site, meeting local building codes.
Park model RVs: Recreational vehicles designed for long-term placement, often used as seasonal or vacation housing.
Accessory dwelling units (ADUs): Secondary housing units on a single-family residential lot, such as backyard cottages or in-law suites.
Integrated business model: A company structure where multiple stages of production and distribution are controlled within the same organization.
Institutional clients: Organizations such as pension funds, insurance companies, or investment firms that invest large sums of money.

Buffett's actions speak volumes.

You won't find Warren Buffett spreading doom and gloom. That isn't his style. Buffett has always been an optimist at heart, even during the most perilous days of the 2008 financial crisis.

However, Buffett is sending a clear warning as 2026 approaches. How? He has been a net seller of stocks for 12 consecutive quarters – the longest such streak ever since he took over Berkshire Hathaway (BRK.A +0.14%) (BRK.B +0.19%). This reflects an unprecedented negative outlook for Buffett as he prepares to step down as Berkshire's CEO at the end of the year.

The "Oracle of Omaha" isn't publicly predicting what he thinks is about to happen with the stock market. He isn't telling investors specific steps to take, either. However, his actions speak volumes. Here are three things investors should do, based on what Buffett is doing himself.

Image source: The Motley Fool.

1. Don't panic
People often refer to Buffett's quote, "[W]e simply attempt to be fearful when others are greedy and to be greedy only when others are fearful." There's a good case to be made that Buffett is fearful right now.

It can be tempting to equate the fear Buffett referenced with panic. But the legendary investor would never recommend panicking.

Sure, Buffett has sold numerous stocks in recent quarters. He wouldn't be a net seller of stocks if that were not the case. However, he hasn't dumped shares in a frenzy.

Do you want proof that Buffett isn't panicking? Simply look at Berkshire's portfolio. It still includes more than 40 stocks valued at over $300 billion. If Buffett were truly nervous about the future, Berkshire wouldn't have so much money tied up in the stock market.

Buffett has held onto positions for which he's most comfortable over the long term, including stalwarts such as American Express (AXP 0.20%) and Coca-Cola (KO 0.64%). That's a good strategy for other investors. Sell any stocks for which you have a lower conviction. Keep those you like the most. And, most importantly, remain calm.

2. Build cash
In the same letter to Berkshire Hathaway shareholders where Buffett provided his famous "be fearful" quote, he also wrote:

As this is written, little fear is visible in Wall Street. Instead, euphoria prevails-and why not? What could be more exhilarating than to participate in a bull market in which the rewards to owners of businesses become gloriously uncoupled from the plodding performances of the businesses themselves. Unfortunately, however, stocks can't outperform businesses indefinitely.

Those words were written in 1987 during a strong bull market, but they remain just as applicable today. The S&P 500 (^GSPC +0.19%) has skyrocketed to all-time highs. Many investors are fearful, but not in the way Buffett prescribed. They have FOMO -- the fear of missing out.

Buffett, though, understands that the boom will eventually come to a grinding halt. He wouldn't attempt to predict exactly when it will happen. However, he wants Berkshire to be prepared when it does. That's why he has amassed the largest cash stockpile in the company's history – around $382 billion.

BRK.A Cash and Short Term Investments (Quarterly) data by YCharts

Building cash is a smart idea for retail investors, too. It puts you and me in a good position to invest in wonderful companies when prices become more attractive. And with short-term U.S. Treasuries yielding north of 3.5%, you'll still make at least a little money as you wait.

3. Buy selectively
When some hear that Buffett has been a net seller of stocks for 12 consecutive quarters, they might think he hasn't been buying any stocks at all. That's not the case. Buffett has bought some stocks. However, he is buying selectively.

This doesn't mean that Buffett has changed his criteria for investing in stocks because he's worried about the market or the economy. Instead, he remains consistent in applying the criteria he uses, regardless of what's happening externally.

To be specific, Buffett is only buying stocks for Berkshire's portfolio that have attractive valuations relative to their growth prospects. That's exactly what he has done for decades. This is a prudent approach for any investor. Establish your criteria for buying a stock. Make sure it's sound. Then stick to it, selling only when the stock no longer meets your initial investment thesis.

Buffett once used a baseball metaphor to make his point, "The stock market is a no-called-strike game. You don't have to swing at everything – you can wait for your pitch." No matter what's in store for the stock market, wait for your pitch and buy selectively.

One fund just doubled down on a beaten-down tax-tech leader—here’s what they may be seeing that the market isn’t.

On November 14, California-based Tensile Capital Management disclosed a buy of 160,559 shares of Vertex (VERX +1.18%) in the third quarter. Despite the expanded stake, the market value of the position decreased by approximately $34.4 million, according to an SEC filing.

What HappenedAccording to a Securities and Exchange Commission (SEC) filing dated November 14, Tensile Capital Management LP increased its stake in Vertex by acquiring 160,559 additional shares during the third quarter. The post-trade holding reached 3.8 million shares valued at $94.3 million as of September 30.

What Else to KnowVertex makes up about 11.8% of Tensile’s 13F AUM, making it the fund’s largest position as of September 30.

Top holdings after the filing: 

NASDAQ: VERX: $94.3 million (11.8% of AUM)NYSE: DKS: $79.5 million (9.9% of AUM)NYSE: VVV: $74.7 million (9.3% of AUM)NYSE: LAD: $74.4 million (9.3% of AUM)NYSE: USFD: $58.5 million (7.3% of AUM)As of Friday, VERX shares were priced at $19.68, down a staggering 65% over the past year and well underperforming the S&P 500, which is up 13% in the same period.

Company OverviewMetricValueMarket Capitalization$3.1 billionRevenue (TTM)$732.2 millionNet Income (TTM)($53.6 million)Price (as of market close Friday)$19.68Company SnapshotVertex provides tax technology solutions, including tax determination, compliance and reporting, tax data management, document management, and pre-built integration for corporations across retail, communications, leasing, and manufacturing sectors.The company generates revenue primarily through software licenses and software-as-a-service (SaaS) subscriptions, as well as implementation, training, and tax-related outsourcing services.It targets large enterprises and multinational corporations seeking comprehensive, integrated tax compliance and automation solutions in the United States and internationally.Vertex is a leading provider of tax technology software and services, serving a diverse set of enterprise clients. The company leverages a combination of software licensing and recurring SaaS revenue streams to deliver scalable, integrated solutions for complex tax compliance needs. Its established reputation and broad product suite position Vertex as a strategic partner for organizations aiming to streamline tax operations and manage regulatory risk.

Foolish TakeVertex’s collapse since January has turned it into a contrarian setup: a market leader with strong fundamentals but sharply discounted sentiment. That context makes Tensile’s increased exposure notable, especially as the company just posted double-digit revenue growth and robust cash generation in the third quarter. Vertex delivered 12.7% revenue growth, 29.6% cloud revenue growth, and $43.5 million in adjusted EBITDA, alongside a new $150 million share-repurchase program—meaningful signals for long-term investors evaluating whether the selloff has overshot fundamentals.

Tensile boosted its position to 3.8 million shares valued at $94.3 million, even as the stake’s market value fell roughly $34 million during the quarter. The position now represents about 12% of the fund’s 13F assets, far larger than any of its other holdings—implying conviction that the drawdown presents an opportunity rather than deterioration.

Vertex shares trade 65% lower than in late January, materially underperforming both peers and the S&P 500. For long-term investors, the key question is whether recurring revenue metrics—including $648 million ARR, 107% net revenue retention, and expanding cloud mix—can reassert themselves as drivers of valuation once macro and customer-expansion headwinds normalize.

Glossary13F reportable assets under management: The total value of securities a fund manager must report quarterly to the SEC on Form 13F.
AUM (Assets Under Management): The total market value of all investments managed by a fund or investment firm.
Stake: The amount of ownership or interest an investor holds in a company, usually measured by shares owned.
Trailing twelve months (TTM): The 12-month period ending with the most recent quarterly report.
CAGR (Compound Annual Growth Rate): The annualized growth rate of an investment over a specified period, assuming profits are reinvested.
Software-as-a-Service (SaaS): A software delivery model where applications are accessed online by subscription, rather than installed locally.
Implementation services: Professional services that help clients set up and integrate new software or systems into their operations.
Outsourcing services: Contracting external providers to handle business tasks or processes instead of using internal resources.
Tax compliance: The process of ensuring a company meets all tax laws and filing requirements.
Regulatory risk: The potential for losses due to changes in laws or regulations affecting a business.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Quantum computing stocks are plummeting, but one in particular could be a savvy buy right now.

For three years, investors have poured record sums into artificial intelligence (AI) stocks -- particularly those involved with enterprise software, data centers, or designing and manufacturing semiconductors.

Throughout 2025, however, a new theme in the AI landscape has emerged: quantum computing. The quantum AI landscape is split into two categories. On one side there are pure plays like IonQ, Rigetti Computing, and D-Wave Quantum. On the other side, cloud hyperscalers Amazon, Alphabet, and Microsoft are each exploring custom quantum chip designs.

Let's take a look at how the quantum computing trade has performed over the last year. From there, I'll detail why Nvidia (NVDA 0.56%) is my top pick in a packed field of quantum AI contenders right now.

Image source: Getty Images.

What is going on with quantum computing stocks?
The allure of quantum computing lies in the idea that enthusiasts are buying into the idea that this technology will revolutionize sophisticated applications across various fields, including drug discovery, financial risk modeling, manufacturing, logistics, energy management, and more.

While intriguing, quantum computing remains primarily a theoretical and exploratory endeavor -- hinging on simulations as opposed to measurable commercial adoption.

Nevertheless, quantum pure-play stocks have become all the rage among AI investors. Over the last year, shares of Rigetti Computing have soared by as much as 1,770% while D-Wave Quantum stock gained over 1,500% at its peak.

While this level of momentum might suggest that investing in quantum computing stocks is a no-brainer, smart investors are digging deeper.

IONQ data by YCharts.

All of the quantum pure plays are trading materially lower than their all-time highs, with the most pronounced selling activity occurring over the last month. Adding insult to injury, history suggests these stocks could plummet even further -- potentially losing 80% of their value.

The reason for the sell-off can be summed up in a few talking points:

IonQ has spent $2.5 billion on acquisitions, funding these deals almost exclusively through stock issuances. While IonQ's revenue exceeded Wall Street's expectations, the caveat to note is that much of this growth has been inorganic -- coming from acquisitions. Meanwhile, the company remains deeply unprofitable.
Rigetti Computing's CEO sold $11 million worth of stock back in May when shares were only $12. More recently, management expressed that Rigetti is primarily in a research and development stage right now -- suggesting that meaningful revenue and profitability remain years away.
Several executives at D-Wave, including CEO Alan Baratz, have engaged in heavy insider selling throughout 2025.

Investors are beginning to wake up to the idea that quantum pure-play AI stocks are more favored by aggressive day traders than prudent institutional investors. Against this backdrop, the soaring valuations and current sell-off seen across IonQ, Rigetti, and D-Wave more than echo a potential dot-com-style bubble-bursting event.

Why is Nvidia stock selling off?
Since Nvidia reported financial results for its fiscal third quarter on Nov. 19, shares have dropped by as much as 5%. While this may not seem meaningful, even a nominal decline can erase hundreds of billions in market capitalization for a company that was valued at $5 trillion just a few weeks ago.

One of the biggest concerns surrounding Nvidia is whether the acceleration of AI infrastructure investment from the hyperscalers is sustainable. Skeptics contest that big tech is spending too heavily on capital expenditures (capex). Should these companies tighten their infrastructure budgets, Nvidia could face a meaningful deceleration in revenue growth and profit margins.

In addition, Alphabet's success with its custom chip architecture -- called Tensor Processing Units (TPUs) -- is beginning to eat away at the narrative that Nvidia is king of the chip realm.

Should you buy the dip in Nvidia stock right now?
While the concerns explored above are valid, I think they are overblown.

Today's Change

(

-0.56

%) $

-1.03

Current Price

$

182.35

On the chip side of the equation, Alphabet's TPUs are geared for custom workloads such as deep learning. By contrast, Nvidia's GPUs are more purpose-built or multifaceted pieces of hardware that are used across a number of different generative AI platforms and use cases.

Regarding AI infrastructure, forecasts from McKinsey & Company are calling for nearly $5 trillion to be spent on upgrading data centers, servers, and networking equipment through 2030. These tailwinds bode well for Nvidia, and in some ways are already becoming evident. The company has more than $300 billion in backlog for its current Blackwell GPUs, upcoming Rubin architecture, and accompanying data center products.

Moreover, Nvidia just linked up with Anthropic in a multibillion-dollar deal in which the AI developer will be leveraging Rubin chips for its next-generation models.

In addition to AI infrastructure, Nvidia is expanding its addressable market into software through a new partnership with Palantir Technologies as well as the telecommunications industry via a strategic investment in Nokia.

Lastly, Nvidia recently unveiled some new products in its quantum computing roadmap, including NVQLink interconnect services, which will complement the company's existing CUDA-Q software system.

Right now, Nvidia trades at a forward price-to-earnings (P/E) multiple of just 23.5. Simply put, Nvidia stock hasn't been this cheap since April (when shares crashed after the "Liberation Day" tariff announcement).

In my eyes, Nvidia stock is becoming too cheap to ignore. The company's revenue and profits remain robust, demand and future business visibility is through the roof, and its addressable market is expanding -- making Nvidia a compelling long-term opportunity.

Against this backdrop, I think now is a great time to buy the dip in Nvidia.

A newly public real-estate platform is putting up numbers that look far more seasoned than its age.

On November 14, New York City-based Newtyn Management disclosed in a U.S. Securities and Exchange Commission filing that it sold out its entire Millrose Properties (MRP +0.60%) stake, a move valued at approximately $23 million.

What HappenedAccording to an SEC filing on November 14, Newtyn Management exited its entire holding in Millrose Properties, selling 807,135 shares. The estimated value of the trade was $23 million based on reported quarterly average prices. The position was previously 3.5% of the end of the second quarter.

What Else to KnowTop holdings after the filing: 

NASDAQ:INDV: $101.3 million (12.4% of AUM)NASDAQ:QDEL: $79.5 million (9.7% of AUM)NASDAQ:TBPH: $72.3 million (8.8% of AUM)NYSE:AD: $67.5 million (8.3% of AUM)NYSE:CNNE: $62.5 million (7.6% of AUM)As of Friday, MRP shares were priced at $31.71, up 47.5% since its February spin-off.

Company OverviewMetricValueMarket capitalization$5.3 billionRevenue (TTM)$411 millionNet income (TTM)$191.8 millionDividend yield5.7%Company SnapshotMillrose Properties operates a Homesite Option Purchase Platform (HOPP'R), facilitating residential land banking and providing homebuilders with capital-efficient access to controlled land positions.Primary customers include institutional and large-scale homebuilders seeking flexible land acquisition strategies in the U.S. residential real estate market.The company is positioned as a differentiated partner in the residential REIT sector, focusing on recurring revenue and capital efficiency.Millrose Properties specializes in residential real estate solutions, leveraging its HOPP'R platform to enable homebuilders to efficiently secure land for future development. The company's strategy centers on providing investors with access to income-generating, real estate-backed opportunities traditionally limited to institutional participants.

Foolish TakeEven with shares rallying since their February spin-off, Millrose Properties’ latest results show why some investors may still be rotating exposure rather than exiting on concerns. Millrose is scaling at a pace unusual for a newly listed residential-land platform, redeploying capital as fast as it recycles it, and producing predictable, contract-based cash flow. For long-term investors, the combination of rising guidance, strengthened liquidity, and accelerating non-Lennar partnerships helps clarify the company’s trajectory as it transitions fully into its post-spin identity.

The portfolio has expanded meaningfully: Millrose generated $852 million in net homesite sale proceeds, including $766 million from Lennar, and redeployed $858 million back into Lennar-related land acquisitions in the third quarter. Under other builder agreements, funding reached $770 million, lifting invested capital outside Lennar to $1.8 billion, at an attractive 11.3% weighted-average yield. Management also completed $2 billion in senior notes offerings, eliminating near-term maturities and boosting liquidity to $1.6 billion.

For long-term investors, the takeaway is that Millrose is behaving less like a fragile spin-off and more like a maturing capital-recycling engine: high-yielding assets, strong liquidity, and secular demand from national builders. And all of this to say it doesn't seem unusual for a fund to lock in profits here and reallocate to ideas with more upside.

GlossaryAssets under management (AUM): The total market value of investments managed by a fund or investment firm.

13F filing: A quarterly report required by the SEC, disclosing holdings of institutional investment managers.

Dividend yield: Annual dividends paid by a company divided by its share price, expressed as a percentage.

Trailing twelve months (TTM): The 12-month period ending with the most recent quarterly report.

Land banking: The practice of acquiring and holding land for future development or sale.

Capital-efficient: Using the least amount of capital necessary to achieve a desired investment or business outcome.

REIT: Real Estate Investment Trust; a company owning or financing income-producing real estate.

Institutional investor: An organization, such as a fund or insurance company, that invests large sums of money.

Homesite Option Purchase Platform (HOPP'R): A platform allowing homebuilders to secure future land development rights with flexible terms.

Stake: The ownership interest or investment held in a company by an individual or institution.

Sell-out: The complete sale of an investment position, reducing ownership to zero.

A record movement of 23 561 billion SHIB in just 24 hours shook the crypto community. Historic anomaly, technical error or manipulation?

Bitcoin stayed close to $89,000 on Sunday, holding inside a narrow trading range as the broader crypto market continued to drop. The global crypto market cap slipped to $3.01 trillion.

Compared to earlier in the month, trading volumes have slowed. Recent price swings have been small, and the market has yet to show a clear direction. This lack of energy has kept BTC stuck below important resistance levels and prevented any strong recovery attempts.

Resistance Blocks BreakoutsBitcoin has repeatedly struggled to break past the $92,000–$93,000 resistance band. Each time the price has attempted an upward push, sellers have stepped in and pushed it back down, showing that the market is still facing pressure from profit-taking and derivative unwinding. Until this resistance zone is convincingly cleared, analysts say upside momentum will likely remain limited.

On the downside, support between $86,000 and $88,000 continues to act as the main cushion for the price. Experts are watching this area closely because a clear break below it could trigger fresh selling and possibly send Bitcoin toward the lower $80,000 range. For now, buyers are managing to defend this zone, keeping the market in a sideways phase.

Broader Market Moves in SyncMajor altcoins such as Ethereum, BNB, Solana, and XRP also cooled off, showing Bitcoin’s quiet trading pattern. The average market RSI hovering around 39 suggests mild oversold pressure but not enough to confirm a reversal. The market appears to be waiting for new economic cues or strong inflows that could shift momentum.

What Comes Next?Until a breakout from this tight range occurs, Bitcoin is expected to continue moving sideways. A move above $92,000 would be the first sign of strength, while a drop under $86,000 may confirm further weakness.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Bitcoin (BTC) fell below $88,000 into Sunday’s weekly close as traders eyed weakness into a major US macro event.

Key points:

Bitcoin sees snap volatility into the weekly close, dipping close to $87,000.

Traders expect weaker BTC price action into the Fed interest-rate decision.

Bulls need to keep hold of $86,000, says analysis.

BTC price wobbles as weekly candle completesData from Cointelegraph Markets Pro and TradingView showed BTC price volatility returning, with BTC/USD losing $2,000 over two hourly candles.

BTC/USD one-hour chart. Source: Cointelegraph/TradingView
The move ended an uneventful weekend, and opened the door to a potential new “gap” forming on CME Group’s Bitcoin futures markets. As Cointelegraph reported, price tends to “fill” such gaps quickly once the new macro trading week begins.

“In 6 months, we have filled every single CME gap,” trader Killa noted in part of commentary on X.

BTC/USD chart with CME futures gap target. Source: Killa/X
In a separate post, Killa added that Mondays often formed the basis for price action for the rest of the week.

“Mondays are typically when pivot highs and lows form with weekend price action being a deciding factor,” he explained. 

“If the weekend doesn’t pump, it increases the probability of a pivot low forming on Monday. If we do get a weekend pump, it increases the chances of Monday forming a pivot high.” BTC/USD chart with Mondays highlighted. Source: Killa/XFOMC bets focus on Fed cutMarket participants meanwhile were broadly focused on the key macroeconomic topic of the week: the US Federal Reserve’s decision on interest-rate changes.

Markets continued to expect a 0.25% cut result from Wednesday’s meeting of the Federal Open Market Committee (FOMC), data from CME Group’s FedWatch Tool confirmed.

“The rate call is easily the #1 event of the week - liquidity, risk appetite and positioning all hinge on it. We also get a delayed JOLTS report worth watching,” private investment manager Peter Tarr wrote on the topic at the weekend. 

“Most expect a 25 bps cut.” Fed target rate probabilities for Dec. 10 FOMC meeting (screenshot). Source: CME Group
Bitcoin often sees downward pressure into FOMC announcements, which can spark significant volatility as markets assess Fed officials’ language for hints over future policy changes.

Commenting, crypto trader, analyst and entrepreneur Michaël van de Poppe suggested that FOMC nerves could spark a retreat to $87,000.

“After that, bounce back up, swiftly, in which the uptrend is confirmed for Bitcoin and it's ready to break $92K and therefore the run towards $100K in the coming 1-2 weeks as the FED is reducing QT, doing rate cuts and expanding the money supply to increase the business cycle,” he told X followers.

Van de Poppe put $86,000 as bulls’ line in the sand.

BTC/USDT four-hour chart with volume, RSI data. Source: Michaël van de Poppe/XThis article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision. While we strive to provide accurate and timely information, Cointelegraph does not guarantee the accuracy, completeness, or reliability of any information in this article. This article may contain forward-looking statements that are subject to risks and uncertainties. Cointelegraph will not be liable for any loss or damage arising from your reliance on this information.

17h05 ▪
4
min read ▪ by
Evans S.

Summarize this article with:

Bitcoin Cash has an early year that few observers anticipated. While most L1 blockchains struggle to stand, BCH moves forward confidently, as if the entire market has finally decided to reconsider its place in the crypto landscape. A sharp, almost disorienting rise that contrasts with the lethargy of other major networks.

In brief

Bitcoin Cash posts a spectacular 40% increase, dominating all L1 blockchains in 2025
Its performance is based on a healthy supply dynamic and growing institutional interest
Meanwhile, Bitcoin is preparing for a technical pause before a possible move towards six figures.

A bullish movement fueled by an almost exemplary supply dynamic
According to data compiled by analyst Crypto Koryo, Bitcoin Cash rose to the top of L1 performances in 2025. With nearly a 40% increase, it clearly distances itself from BNB, Hyperliquid, Tron, or XRP, whose gains remain modest.

While Bitcoin ETFs are experiencing massive withdrawals from institutional investors, BCH establishes itself as one of the few L1s capable of maintaining a clearly positive momentum. Meanwhile, more established networks like Ethereum, Solana, Avalanche, Cardano, or Polkadot suffer declines often exceeding 50%. This marked contrast highlights how much new attention Bitcoin Cash has been capturing within the market this year.

The key element seems to come from the very structure of its supply. No token unlocks in the backlog. No foundation treasury likely to generate massive selling pressure. No VCs lurking, ready to dump tokens at the slightest clearing. The entire supply is already circulating, freed from the institutional weights that hinder many other projects. This mechanical scarcity creates fertile, almost ideal ground for a sustainable price appreciation.

Remarkably, this dynamic takes hold even though Bitcoin Cash no longer has an official X account to orchestrate its communication. An absence that, paradoxically, strengthens the idea of an organic movement, guided by the market rather than a marketing strategy.

The Bitcoin market prepares for a pause before a possible sprint to six figures
While BCH surprises, Bitcoin itself might experience a more classic interlude. According to trader Michaël van de Poppe, the most likely scenario involves a technical pullback to $87,000. A brief correction designed to clear excesses before the Fed meeting and give the market the necessary oxygen for its next surge.

In his reading, everything revolves around two levels: $86,000 as vital support and $92,000 as a bullish pivot. A clear rebound above the latter threshold could propel BTC to $100,000 within one to two weeks.

A timing that would coincide with a more favorable macro environment, marked by a tightening of quantitative tightening, the first prospects of rate cuts, and expansionary monetary creation again. But caution remains warranted. A break below $86,000 or the inability to reclaim $92,000 would invalidate this scenario, leaving the door open to a drift toward $80,000.

Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.

Join the program

A

A

Lien copié

Evans S.

Fascinated by Bitcoin since 2017, Evariste has continuously researched the subject. While his initial interest was in trading, he now actively seeks to understand all advances centered on cryptocurrencies. As an editor, he strives to consistently deliver high-quality work that reflects the state of the sector as a whole.

DISCLAIMER

The views, thoughts, and opinions expressed in this article belong solely to the author, and should not be taken as investment advice. Do your own research before taking any investment decisions.

Solana co-founder Anatoly Yakovenko has voiced strong opposition to Coinbase’s Base network’s latest expansion strategy. The controversy stems from Base’s introduction of a new bidirectional bridge, which Yakovenko dismisses as misleading and detrimental to Solana’s interests.

Solana, a rapidly growing blockchain network known for its high-speed transactions, finds itself at odds with Base, an Ethereum layer-2 network. On December 7, Yakovenko openly criticized Base’s bridge initiative. He argued that such cross-chain bridges are not neutral and serve as mechanisms for economic gain, ultimately benefiting one network at the expense of another. This sentiment reflects broader concerns within the blockchain community about the true intentions behind inter-network bridge projects.

Yakovenko’s main contention is that Base’s applications should transition their computational activities to Solana, ensuring that transaction fees and economic advantages benefit Solana validators. He harshly criticized Base’s bridge, labeling its purported alignment strategy as deceptive. According to him, this strategy is often used to mask the fact that capital might be moving away from Solana.

The friction increased when Jesse Pollak, leader of Base, announced the bridge, presenting it as a tool to facilitate liquidity exchange between ecosystems. Pollak emphasized its two-way functionality, aiming to provide Solana teams access to Base and vice versa. He claimed that the bridge was created in response to specific requests from teams within both ecosystems.

Despite Pollak’s positive framing, Yakovenko accused Base of employing the term “alignment” merely as marketing jargon to disguise its competitive motives. He demanded that Base be transparent about its strategic intentions rather than masking them as cooperative efforts.

Solana’s leadership, including Vibhu Norby and Akshay BD, has expressed additional concerns. They criticized Base for launching the bridge without consulting Solana’s technical and marketing teams, interpreting this as a hostile maneuver. They also pointed to private discussions within Base hinting at ambitions to “flip” Solana, underscoring their skepticism about Base’s intentions.

However, Pollak defended Base’s actions, attributing the discord to communication failures rather than malicious intent. He stressed that the bridge was developed over nine months to meet the demands of developers from both ecosystems. Pollak reassured Solana builders that Base has no desire to monopolize their activities but instead aims to broaden access to the opportunities on Base.

From a broader perspective, Solana and Base are key players in the blockchain space. Together, they manage close to $20 billion in locked value, with Solana accounting for $12 billion and Base holding about $6 billion, according to DeFiLlama data. This sizable economic weight highlights the significance of the ongoing rivalry and the stakes involved in their competitive maneuvers.

Some market observers, like NFT historian Leonidas, see a repeating pattern in Base’s tactics. He argues that Base has previously used similar strategies within the Ethereum ecosystem, capturing developer interest before shifting focus to its own native economy. This historical context raises alarms for Solana stakeholders fearing a similar outcome.

Despite the potential for growth and innovation that such bridges promise, they come with inherent risks. The integration of different blockchain ecosystems can lead to security vulnerabilities, as exemplified by past bridge hacks that resulted in significant losses. The complexities of ensuring seamless and secure interactions between different networks remain a challenge.

As the blockchain industry continues to evolve, the clash between Solana and Base serves as a reminder of the competitive dynamics at play. Collaboration and open communication are crucial to prevent misunderstandings and conflicts that could hinder progress.

In conclusion, the development of cross-chain bridges between blockchain networks like Solana and Base reflects both the promise and peril inherent in the rapidly growing crypto landscape. While these bridges offer the potential for expanded opportunities and liquidity, they also pose challenges related to trust, security, and strategic alignment. The ongoing discourse between Solana and Base underscores the importance of transparency and genuine collaboration in realizing the full potential of blockchain technology.

Post Views: 11

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

The last day of the week is controlled by bears, according to CoinStats.

Top coins by CoinMarketCapSHIB/USDThe rate of SHIB has declined by 1.76% over the last day.

Image by TradingViewOn the hourly chart, the price of SHIB is testing the local support of $0.00000833. If a breakout happens and the daily bar closes below that mark, the correction is likely to continue to the $0.00000820 range.

Image by TradingViewOn the bigger time frame, the rate of SHIB is far from the key levels. The volume has declined, which means neither buyers nor sellers are dominating at the moment.

You Might Also Like

In this case, sideways trading around the current prices is the more likely scenario over the next few days.

Image by TradingViewFrom the midterm point of view, the situation is similar. However, if bulls lose the interim level of $0.00000750, traders may see a test of the $0.00000678 support shortly.

SHIB is trading at $0.00000832 at press time.

Notcoin (NOT) experienced an impressive price increase of nearly 36%, driven by unexpected speculative interest in this Telegram-based token. Despite the initial excitement, the surge quickly dissipated, marking the most significant selling period in the past six months.

The correlation between Notcoin and Bitcoin has substantially weakened, dropping to 0.43. This represents a notable shift from the past, where Notcoin closely mirrored Bitcoin’s performance. The reduced correlation can be beneficial for Notcoin, particularly if Bitcoin continues to experience volatility or further losses, as Notcoin may not face the same direct downward pressure. However, the separation from Bitcoin also introduces new challenges. Should Bitcoin experience a strong recovery, it could divert liquidity from smaller, speculative tokens like Notcoin, potentially driving its value down, even if investor sentiment towards Notcoin remains stable.

The Chaikin Money Flow (CMF) indicator has shown a significant decrease over the past day, indicating heavy outflows from Notcoin. The indicator’s movement into negative territory suggests that investors quickly offloaded their positions during the rally. This behavior is likely driven by profit-taking or a desire to minimize exposure, leading to a sharp pullback in Notcoin’s price.

This wave of selling pressure undermines the initial bullish momentum that propelled Notcoin’s surge. Without a reversal of these outflows and a stable market environment, any short-term recovery attempts could be hindered. For Notcoin to regain its footing, renewed accumulation and overall market stability are essential.

During the recent surge, Notcoin’s price reached a high of $0.000750 before correcting to $0.000615. This swift correction reflects a cooling of earlier enthusiasm, consistent with the outflow trends indicated by market metrics. If Bitcoin starts to recover, Notcoin might face difficulties, as larger and more stable assets often attract liquidity during such times. Should this occur, Notcoin risks falling below its $0.000609 support level, which could lead to a further decline toward $0.000552.

On the flip side, if Bitcoin experiences another downturn and Notcoin investors regain optimism, the token could find stability at the $0.000609 support level. A successful rebound from this point could push the price towards $0.000723, potentially challenging the current bearish sentiment.

Historically, smaller cryptocurrencies like Notcoin have struggled with volatility, particularly when investor interest wanes or when the broader market faces downturns. The cryptocurrency market, known for its rapid and often unpredictable movements, offers opportunities but also significant risks to investors. Notcoin’s recent experience highlights the delicate balance between speculative gains and the inherent risks of quick sell-offs.

Compared to established cryptocurrencies, Notcoin and similar tokens face additional challenges in gaining and maintaining investor trust. Larger cryptocurrencies benefit from more considerable market capitalization, widespread recognition, and generally more stable price movements, making them attractive during uncertain times.

A major risk for Notcoin is its reliance on speculative interest, which can be fickle. Should investor enthusiasm wane or shift to more established assets, Notcoin could see continued pressure. Additionally, regulatory changes in the cryptocurrency space could impact smaller tokens more severely, as they often lack the resources and infrastructure to quickly adapt to new rules.

In the broader context, the cryptocurrency market’s rapid evolution has brought both challenges and opportunities. While the potential for high returns attracts many investors, it also demands a cautious approach given the associated volatility and risk factors. Notcoin’s recent price movements serve as a reminder of the importance of diversification and the need for investors to remain vigilant in a rapidly changing market landscape.

In recent years, the cryptocurrency market has seen a surge of new tokens, with many attempting to differentiate themselves through unique platforms or innovative technologies. However, the crowded marketplace makes it difficult for new entrants to sustain long-term growth, particularly if they lack a clear competitive advantage.

As Notcoin navigates the coming weeks, its ability to stabilize and attract renewed interest will be crucial. Investors will be closely watching how the token reacts to broader market trends and whether it can maintain or increase its value independently of Bitcoin’s influence. Despite the recent volatility, Notcoin’s performance could serve as a case study in the potential and pitfalls of smaller cryptocurrencies navigating the complex and rapidly evolving digital asset landscape.

Post Views: 9

In brief
In a June, Edelman shook up the investment world by recommending 10%-40% crypto allocations in portfolios.
The founder of the influential Digital Assets Council of Financial Professionals views the current environment as an opportunity to buy the asset.
Bitcoin's reaction to macroeconomic uncertainty along with more traditional assets is a sign of its maturity, he said.
Ric Edelman isn’t budging from the groundbreaking cryptocurrency investment strategies he urged six months ago, even as Bitcoin lingers far from its record-breaking heights.

The founder of the Digital Assets Council of Financial Professionals views the current environment—with Bitcoin falling back below $90,000 going into the weekend—as an opportunity to buy the asset before it inevitably regains momentum.

“Right now, the message is simple and compelling,” he recently told Decrypt. “If you liked Bitcoin at $100,000 or $125,000, you have to love it at $85,000. This is the same message that advisors give their clients anytime the stock market declines, and we have seen 20%-30% declines in the S&P 500 as well.”

He added: “We know that market periods of significant decline represent buying opportunities for long-term investors. The same is true here for crypto.” 

In a white paper released in June, Edelman recommended a 10% crypto allocation for conservative investors and up to 40% for more aggressive portfolios, shaking up a financial advisory world that has been slow to embrace digital assets.

Ric Edelman. Photo: Ric EdelmanThe co-founder of Edelman Financial Engines—a nearly $300 billion asset manager—had previously advocated for “low single-digits” investments in crypto, but said he had been swayed by “dramatically improved regulatory clarity and institutional engagement in crypto.” 

Bloomberg Senior ETF Analyst Eric Balchunas called Edelman’s remarks “the most important full-throated endorsement of crypto from [the] TradFi world since Larry Fink.”

Holy smokes. This is the arguably the most important full throated endorsement of crypto from TradFi world since Larry Fink. This guy is Mr RIA. Manages $300b for 1.3million clients. Tops the Barron’s list of America Advisors regularly. https://t.co/3GlOpmB03z

— Eric Balchunas (@EricBalchunas) June 30, 2025

At the time of the paper’s release, Bitcoin had surged more than 32% over a 10-week period on its way to multiple record highs, as the Trump administration’s digital asset policies reshaped the investment landscape, BTC exchange-traded funds mushroomed, and treasuries gobbled up the asset. 

But the largest cryptocurrency by market capitalization has recently struggled to break $90,000, falling as low as $81,000 in November as investors wrestled with macroeconomic turmoil that has weighed on risk assets. Edelman, though, has remained unbowed. 

He said that institutional investors’ ongoing optimism about cryptocurrencies and the widening adoption of blockchain networks underpinning these assets trumped concerns about crypto markets’ price swoon. He noted Harvard University’s regulatory filing last month showing a $116 million position in the BlackRock iShares Bitcoin Trust (IBIT), the largest ETF tracking the market, among other institutions investing in crypto and related products.

“We are seeing massive levels of engagement and adoption, not just by traditional finance, but the entire Fortune 500,” Edelman said. “This can only serve to support and increase prices over the next several years.”

Edelman called current price trends “routine” and no different than for other assets vulnerable to wider forces that prompt investors to take profits after lengthy price climbs. He concurred with other market observers who believe BTC sank as some early whales looked to cash in on early bets.

In his white paper, Edelman predicted that Bitcoin would reach a $19 trillion market capitalization—up more than 955% from its current value of nearly $1.8 trillion—and that given rising life expectancies, even 90-year olds should consider exposure to digital assets with their decisions based on risk tolerance, not age. 

He said that Bitcoin’s struggles are, if anything, a sign of its maturing. 

“It's testimony to the fact that being lumped together with all other asset classes demonstrates better than ever that Bitcoin has become a mainstream asset, and that institutional investors are now treating Bitcoin the same way they're treating everything else,” he said. “That would not have been the case five, 10 years, or 15 years ago. The fact that it's the case today demonstrates the stability, permanence, and continued growth of crypto adoption by the institutional market.”

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

XRP trades at $2.03 with a 7.26% weekly drop and a 6.86% monthly decline as of writing, yet the token shows a remarkable shift in institutional demand that stands out while the broader market struggles. 

The latest WisdomTree report highlights a pattern that contradicts short-term price weakness and points to long-term structural interest from professional investors.

Europe Sets the Tone for Institutional ConfidenceEurope drives one of the clearest accumulation trends in digital assets this year. XRP attracts $549 million in new institutional money, which marks a level unmatched by every major altcoin. Ethereum brings in $185 million, while Solana sees heavy deterioration after its earlier $814 million run. Bitcoin remains ahead with $1.764 billion, yet Europe’s interest in XRP signals a shift within a region known for strict regulatory standards and cautious allocation practices.

Institutional flows in Europe often shape global sentiment because allocators in the region emphasize compliance, long-term positioning, and infrastructure-grade assets. XRP’s presence in that group signals growing comfort with its liquidity profile and expanding utility. The trend also shows interest that forms during market stress and not during hype cycles. This gives the European inflow structure a weight that strengthens the broader global picture.

Global Markets Mirror Europe’s PatternOutside the United States, XRP records $252 million in new inflows this year. Bitcoin products take in $268 million, yet Bitcoin products remain more than twenty-five times larger. The data reveals a dramatic ratio: institutions put almost twenty-five times more fresh capital into XRP than Bitcoin when measured proportionally. That trend shows preference based on function rather than narrative trading.

The pattern continues across Asia and other non-US regions. Market weakness creates an environment where allocators search for resilience and utility. XRP’s architecture supports settlement, compliance alignment, and predictable liquidity movement. Institutions outside the US appear aware of that shift and allocate based on fundamentals rather than speculative narratives.

United States Begins Accelerating XRP ExposureThe US synthetic XRP product records $241 million in inflows this year. That figure surpasses the $206 million added to Solana’s synthetic product. Every other altcoin product in the synthetic category trails far behind. The timing of this inflow matters because US markets saw $6.4 billion exit Bitcoin and Ethereum ETFs in November. Investors who cut exposure from the two largest assets still moved capital into XRP products.

This shows a critical change in US institutional behavior. Allocators search for tokens that position themselves inside the regulated finance stack instead of tokens that depend on speculative cycles. XRP finds momentum at a time when capital usually flees risk markets. That timing strengthens the broader signal of global preference.

GTreasury Acquisition Strengthens XRP’s Role in Enterprise SystemsRipple’s acquisition of GTreasury, a platform that connects to financial operations used by major corporations, provides XRP with integration into workflows that manage $12.5 trillion in enterprise liquidity. Corporate teams use GTreasury for cross-border payments, payroll routes, working capital, and supply-chain networks. Analysts note that this embeds XRP into real-time settlement rails inside environments where treasurers control billions in daily liquidity.

This creates a shift from speculative use toward operational finance. XRP evolves into back-end infrastructure rather than a retail-driven trading asset. The integration strengthens its utility profile and supports the institutional inflow data visible across global markets.

XRP Outperforms a Declining MarketWisdomTree data confirms that XRP posts the only positive YTD return among major cryptocurrencies in 2025 with a 4% gain, showing resilience in a year defined by macro tightening and risk-off behavior.

Institutional flows across Europe, Asia, non-US regions, and the United States all point to the same conclusion. Professional capital now treats XRP as an operational asset aligned with the future of regulated global settlement. Price performance lags in the short term, yet preference from institutional allocators often arrives long before major price expansion.